New orphan drug designation for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease

Written by Alice Weatherston

A recent announcement by Addex Therapeutics (Geneva, Switzerland) has highlighted the designation of dipraglurant by the US FDA as an orphan drug for the treatment of levodopa-induced dyskinesia associated with Parkinson’s disease (PD-LID). The development signals a key sign of support for the use of the drug in this rare disease. Dipraglurant was developed as a small molecule inhibitor of the metabotropic glutamate receptor 5 (mGluR5), with the potential for use in combination with levodopa or dopamine agonists, or as a standalone treatment for Parkinson’s disease levodopa-induced dyskinesia, other motor and non-motor symptoms of Parkinson’s disease and other movement disorders....

To view this content, please register now for access

It's completely free